Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2000

View Archived Issues

Inhibition of NK cells by cancer cells from patients with CML prevented by Maxamine

SangStat's Thymoglobulin granted orphan drug designation in U.S.

The hypothalamo-hypophyseal-adrenal axis influences arthritis development, treatment

Lisinopril found to regress myocardial fibrosis in hypertensive patients

Consensus on Statins -- International Task Force Webcast now available on demand

Vernalis's clinical development programs continue to make good progress

ImmunoGen/SmithKline Beecham open second trial of cancer treatment

Antidepressants with novel mechanism of action identified at SB

AstraZeneca presents new DOP-selective analgesic candidate in Bologna

MBR ligands under development at Dainippon as safe and effective anxiolytic agents

SRI reports synthesis and activity of new anti-MAC compounds targeting DHFR

Novel anti-MRSA cephalosporin and prodrug emerge from Microcide/R.W. Johnson collaboration

Coulter acquires rights to anticancer compounds

Broad-spectrum antiherpesvirus agents from Pharmacia target viral polymerase

Zefix approved in Japan for chronic HBV infection

Japanese approval granted for Diovan, a new antihypertensive agent

Merck discusses preparation and methods of using integrin antagonists for bone disorders, etc.

Synthesis and use of quinazoline-based VEGF receptor tyrosine kinase inhibitors

Research program at SB on orexin receptor antagonists yields results

Roche discloses novel MMP inhibitors particularly useful in the control of cancer

Lactam factor Xa inhibitors designed by BMS research groups

Protein farnesyltransferase inhibitors and their use in cancer treatment described by Pfizer

Merck patents new series of tachykinin NK1 receptor antagonists

Aptosyn NDA for FAP indication not approvable at this time

FDA denies approval of Foscan

Promising antischizophrenia agent shows safety and efficacy in phase III

Vical reports interim data from phase II trial of Leuvectin

Corixa and Purdue establish agreement for therapeutic antibodies for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...